Antidiabetic Activity of Zinc Oxide and Silver Nanoparticles on Streptozotocin-induced Diabetic Rats

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2014 Jan 31

PMID 24477262

Citations 65

Authors

Ali Alkaladi

Aaser Mohamed Abdelazim

Mohamed Afifi

Affiliations

Soon will be listed here.

Abstract

The use of nanoparticles in medicine is an attractive proposition. In the present study, zinc oxide and silver nanoparticles were evaluated for their antidiabetic activity. Fifty male albino rats with weight 120 ± 20 and age 6 months were used. Animals were grouped as follows: control; did not receive any type of treatment, diabetic; received a single intraperitoneal dose of streptozotocin (100 mg/kg), diabetic + zinc oxide nanoparticles (ZnONPs), received single daily oral dose of 10 mg/kg ZnONPs in suspension, diabetic + silver nanoparticles (SNPs); received a single daily oral dose of SNP of 10 mg/kg in suspension and diabetic + insulin; received a single subcutaneous dose of 0.6 units/50 g body weight. Zinc oxide and silver nanoparticles induce a significant reduced blood glucose, higher serum insulin, higher glucokinase activity higher expression level of insulin, insulin receptor, GLUT-2 and glucokinase genes in diabetic rats treated with zinc oxide, silver nanoparticles and insulin. In conclusion, zinc oxide and sliver nanoparticles act as potent antidiabetic agents.

Citing Articles

Evaluation of Hippocampal Microanatomy and Neuro-Biomarkers Following Administration of Silver Nanoparticles Conjugated with Tenofovir Disoproxil Fumarate in Experimental Diabetic Rats.

Lawal S, Olojede S, Alabi B, Dithole K, Matula S, Naidu E Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770477 PMC: 11728639. DOI: 10.3390/ph17121635.

Antidiabetic, anti-inflammatory, antioxidant, and cytotoxicity potentials of green-synthesized zinc oxide nanoparticles using the aqueous extract of .

Nkemzi A, Okaiyeto K, Oyenihi O, Opuwari C, Ekpo O, Oguntibeju O 3 Biotech. 2024; 14(12):291.

PMID: 39507059 PMC: 11535088. DOI: 10.1007/s13205-024-04125-0.

Bibliometric analysis of research on the utilization of nanotechnology in diabetes mellitus and its complications.

Zhang J, He M, Gao G, Sun T Nanomedicine (Lond). 2024; 19(16):1449-1469.

PMID: 39121376 PMC: 11318711. DOI: 10.1080/17435889.2024.2358741.

Fabrication of novel vildagliptin loaded ZnO nanoparticles for anti diabetic activity.

Samad A, Shahid S, Mansoor S, Afzal S, Javed M, Zidan A Sci Rep. 2024; 14(1):17893.

PMID: 39095369 PMC: 11297240. DOI: 10.1038/s41598-024-67420-z.

Docosahexaenoic acid-loaded nanoparticles: A state-of-the-art of preparation methods, characterization, functionality, and therapeutic applications.

Ali A, Hachem M, Ahmmed M Heliyon. 2024; 10(9):e30946.

PMID: 38774069 PMC: 11107210. DOI: 10.1016/j.heliyon.2024.e30946.

References

Wijesekara N, Dai F, Hardy A, Giglou P, Bhattacharjee A, Koshkin V . Beta cell-specific Znt8 deletion in mice causes marked defects in insulin processing, crystallisation and secretion. Diabetologia. 2010; 53(8):1656-68. PMC: 6101216. DOI: 10.1007/s00125-010-1733-9. View

Mocchegiani E, Giacconi R, Malavolta M . Zinc signalling and subcellular distribution: emerging targets in type 2 diabetes. Trends Mol Med. 2008; 14(10):419-28. DOI: 10.1016/j.molmed.2008.08.002. View

Thompson K, Lichter J, LeBel C, Scaife M, McNeill J, Orvig C . Vanadium treatment of type 2 diabetes: a view to the future. J Inorg Biochem. 2009; 103(4):554-8. DOI: 10.1016/j.jinorgbio.2008.12.003. View

Zhang X, Liang W, Mao Y, Li H, Yang Y, Tan H . Hepatic glucokinase activity is the primary defect in alloxan-induced diabetes of mice. Biomed Pharmacother. 2007; 63(3):180-6. DOI: 10.1016/j.biopha.2007.07.006. View

Lee K, Jeong I, Lee S, Oh S, Cho M . Regulation of leptin gene expression by insulin and growth hormone in mouse adipocytes. Exp Mol Med. 2002; 33(4):234-9. DOI: 10.1038/emm.2001.38. View

Van Schaftingen E, Veiga-da-Cunha M, Niculescu L . The regulatory protein of glucokinase. Biochem Soc Trans. 1997; 25(1):136-40. DOI: 10.1042/bst0250136. View

Smidt K, Jessen N, Petersen A, Larsen A, Magnusson N, Jeppesen J . SLC30A3 responds to glucose- and zinc variations in beta-cells and is critical for insulin production and in vivo glucose-metabolism during beta-cell stress. PLoS One. 2009; 4(5):e5684. PMC: 2683566. DOI: 10.1371/journal.pone.0005684. View

Brown G . Glucose transporters: structure, function and consequences of deficiency. J Inherit Metab Dis. 2000; 23(3):237-46. DOI: 10.1023/a:1005632012591. View

Hirst S, Karakoti A, Tyler R, Sriranganathan N, Seal S, Reilly C . Anti-inflammatory properties of cerium oxide nanoparticles. Small. 2009; 5(24):2848-56. DOI: 10.1002/smll.200901048. View

10.

Haase H, Overbeck S, Rink L . Zinc supplementation for the treatment or prevention of disease: current status and future perspectives. Exp Gerontol. 2008; 43(5):394-408. DOI: 10.1016/j.exger.2007.12.002. View

11.

Rungby J . Zinc, zinc transporters and diabetes. Diabetologia. 2010; 53(8):1549-51. DOI: 10.1007/s00125-010-1793-x. View

12.

Chausmer A . Zinc, insulin and diabetes. J Am Coll Nutr. 1998; 17(2):109-15. DOI: 10.1080/07315724.1998.10718735. View

13.

Wells I . Evidence that the etiology of the syndrome containing type 2 diabetes mellitus results from abnormal magnesium metabolism. Can J Physiol Pharmacol. 2008; 86(1-2):16-24. DOI: 10.1139/y07-122. View

14.

Lin Y, Sun Z . Current views on type 2 diabetes. J Endocrinol. 2009; 204(1):1-11. PMC: 2814170. DOI: 10.1677/JOE-09-0260. View

15.

White M, Yenush L . The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. Curr Top Microbiol Immunol. 1997; 228:179-208. DOI: 10.1007/978-3-642-80481-6_8. View

16.

Umrani R, Paknikar K . Zinc oxide nanoparticles show antidiabetic activity in streptozotocin-induced Type 1 and 2 diabetic rats. Nanomedicine (Lond). 2013; 9(1):89-104. DOI: 10.2217/nnm.12.205. View

17.

Yih T, Al-Fandi M . Engineered nanoparticles as precise drug delivery systems. J Cell Biochem. 2006; 97(6):1184-90. DOI: 10.1002/jcb.20796. View

18.

Wang Z, Cefalu W . Current concepts about chromium supplementation in type 2 diabetes and insulin resistance. Curr Diab Rep. 2010; 10(2):145-51. DOI: 10.1007/s11892-010-0097-3. View

19.

Tahrani A, Piya M, Kennedy A, Barnett A . Glycaemic control in type 2 diabetes: targets and new therapies. Pharmacol Ther. 2009; 125(2):328-61. DOI: 10.1016/j.pharmthera.2009.11.001. View

20.

Orci L, Unger R, Ravazzola M, Ogawa A, Komiya I, Baetens D . Reduced beta-cell glucose transporter in new onset diabetic BB rats. J Clin Invest. 1990; 86(5):1615-22. PMC: 296911. DOI: 10.1172/JCI114883. View